Analyzing brain waveforms using neuroimaging big data helps improve diagnosis accuracy
A team of researchers from Osaka University and The University of Tokyo developed MNet, an automatic diagnosis system for neurological diseases using magnetoencephalography (MEG) (Figure 1), demonstrating the possibility of making automatic neurological disease diagnoses using MEG. Their research results were published in Scientific Reports.
MEG and electroencephalography (EEG) are essential for diagnosing neurological diseases such as epilepsy. MEG allows for the acquisition of detailed temporal-spatial patterns of human brain activity through the measurement of electro-magnetic field associated with neural activity, extracting detailed time-series signals from 160 sensors. Although information obtained from these tests is important for diagnosis, time and expertise are necessary for reading and analyzing, and abnormal waveform patterns may be missed.
Deep Neural Network (DNN), also known as deep learning, is a subset of machine learning in artificial intelligence (AI) and has drawn attention in recent years as a means for classifying data on various images, videos, and sounds at a high accuracy through a machine learning process using big data.
The AI-powered automatic classification system MNet, which utilizes DNN as a computational framework, is based on a neural network called EnvNet (end-to-end convolutional neural network for environmental sound classification) and can be trained to extract and learn features of neuroimaging signals unique to various neurological diseases from a massive amount of time-series neuroimaging data.
The team expected that the use of DNN would allow for the system to learn the characteristics of neurological diseases from many signals and classify patients with neurological diseases more accurately than conventional methods using waveforms.
With MNet, they tried to classify neuroimaging big data on 140 patients with epilepsy, 26 patients with spinal cord injuries, and 67 healthy subjects. The trained MNet succeeded in classifying healthy subjects and those with the two neurological diseases with an accuracy of over 70% and patients with epilepsy and healthy subjects with an accuracy of nearly 90%. The classification accuracy was significantly higher than that obtained by a support vector machine (SVM), a conventional general machine learning method based on waveforms (relative band powers of EEG signal). Moving forward, this technique will be used for diagnosis of various neurological diseases, evaluation of severity, prognosis, and efficacy of treatment.
“Machine learning is constantly advancing, with new techniques being developed all the time. However, no matter how much analytical methods advance, if the quality of underlying data is poor, a sharp distinction cannot be drawn. We carried out the process of machine learning by utilizing DNN, which processed big data mainly from the Osaka University Hospital Epilepsy Center. We’d like to increase the number and the types of diseases to be diagnosed without sacrificing quality of data so that our technique will be helpful in clinical practice,” says researcher Jo Aoe of Osaka University.
The Latest on: Automatic diagnosis system
via Google News
The Latest on: Automatic diagnosis system
- In-vitro Diagnostics Market Worth $133.34 Billion, Globally, by 2027 at 5.1% CAGR: Verified Market Researchon June 24, 2020 at 5:06 am
Verified Market Research recently published a report, "In-vitro Diagnostics Market by Application (Diabetes, Infectious Diseases, ...
- Maintenance considerations for manual versus automated manual transmissionson June 22, 2020 at 8:22 am
To reap the benefits of an automated manual transmission (AMT), fleets need to focus on four items in the service bay: electrical system integrity, diagnostic capabilities, air quality, and ...
- Sysmex America Launches XF-1600™: New Automated Flow Cytometer Provides Improved Flexibility and Efficiencyon June 17, 2020 at 7:00 am
Sysmex America, Inc., a leading diagnostic solutions company offering hematology, urinalysis, information systems and flow cytometry testing technology for optimal clinical laboratory performance, ...
- GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Healthon June 16, 2020 at 8:21 am
GenMark Diagnostics, Inc. (GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, has been selected by Vidant Health as its primary provider of rapid diagnostic ...
- COVID-19 Impact on Centralized Automated Dispensing Cabinets Market Latest Demand by 2020-2026on June 16, 2020 at 1:06 am
Market Research Engine has published a new report titled as "Centralized Automated Dispensing Cabinets Market Size By Application (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers), ...
- Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19on June 11, 2020 at 3:49 pm
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has ...
- Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrumenton June 9, 2020 at 4:38 pm
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions ... s first-generation instrumented system, which provides an accurate, objective ...
- Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrumenton June 9, 2020 at 4:11 pm
Sofia 1 is Quidel’s first-generation instrumented system, which provides an accurate, objective and automated result ... globe through the development of diagnostic solutions that can lead ...
- Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrumenton June 9, 2020 at 4:00 pm
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnosti ...
- Takara Bio USA, Inc. and bioSyntagma, Inc. Develop Method for Large-Scale Automated COVID-19 Testingon June 8, 2020 at 5:00 am
Takara Bio USA, Inc., with bioSyntagma, Inc. and partners, developed and validated a large-scale automated COVID-19 testing method and seek FDA EUA.
via Bing News